Quality of life in patients with K‐RAS wild‐type colorectal cancer

E-ISSN： 1097-0142|120|2|181-189

ISSN： 0008-543x

Source： CANCER, Vol.120, Iss.2, 2014-01, pp. : 181-189

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS‐BRAF wild‐type colorectal cancer receiving cetuximab or panitumumab

INTERNATIONAL JOURNAL OF CANCER, Vol. 137, Iss. 6, 2015-09 ,pp. : 1467-1474

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cetuximab/Irinotecan-Chemotherapy in KRAS Wild-type Pretreated Metastatic Colorectal Cancer: A Pooled Analysis and Review of Literature.

Reviews on Recent Clinical Trials, Vol. 8, Iss. 2, 2013-06 ,pp. : 101-109

Bentham Science Publishers

Access to resources Recommend Favorite

A Phase II Study of High-Dose Cetuximab plus Irinotecan in Colorectal Cancer Patients with KRAS Wild-Type Tumors Who Progressed after Standard Dose of Cetuximab plus Irinotecan

Oncology, Vol. 84, Iss. 4, 2013-01 ,pp. : 210-213

Karger

Access to resources Recommend Favorite

Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC)

By Lawrence Donna Maschio Michael Leahy Kevin J. Yunger Simon Easaw Jacob C. Weinstein Milton C.

Journal of Medical Economics, Vol. 16, Iss. 12, 2013-12 ,pp. : 1387-1398

Informa Healthcare

Access to resources Recommend Favorite

Detection of K‐ras gene mutation by liquid biopsy in patients with pancreatic cancer

CANCER, Vol. 121, Iss. 13, 2015-07 ,pp. : 2271-2280

John Wiley & Sons Inc

Access to resources Recommend Favorite